Reactome | Spike binds Spike inhibitors

Schema > Reaction > Entries

Spike binds Spike inhibitors Show undefined attributes

authored	[InstanceEdit:9707766] Jassal, Bijay, 2020-11-20
category	binding
compartment	[Compartment:984] extracellular region
created	[InstanceEdit:9707766] Jassal, Bijay, 2020-11-20
crossReference	[DatabaseIdentifier:12020746] Mondo:0100096
dbId	9707827
disease	[Disease:9683912] COVID-19
displayName	Spike binds Spike inhibitors
edited	[InstanceEdit:9707766] Jassal, Bijay, 2020-11-20 [InstanceEdit:9767899] Stephan, Ralf, 2022-03-02 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
eventOf	[Pathway:R-HSA-9694614] Attachment and Entry - Homo sapiens
input	[Complex:R-COV-9694500] S3:M:E:encapsidated SARS-CoV-2 genomic RNA: 7a:O-glycosyl 3a tetramer [extracellular region] [DefinedSet:R-ALL-9707798] Spike inhibitors [extracellular region]
isChimeric	false
isInDisease	true
isInferred	false
literatureReference	[LiteratureReference:9707794] Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19 [LiteratureReference:9707801] Human recombinant soluble ACE2 in severe COVID-19 [LiteratureReference:9707836] Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 [LiteratureReference:9707796] De novo design of picomolar SARS-CoV-2 miniprotein inhibitors [LiteratureReference:9733158] Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial [LiteratureReference:9733167] The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates [LiteratureReference:9733195] A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 [LiteratureReference:9767485] The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms [LiteratureReference:9767467] Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations [LiteratureReference:9767459] Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions [LiteratureReference:9767493] Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin [LiteratureReference:9767461] ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin [LiteratureReference:9766745] Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2 [LiteratureReference:9770357] Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs
maxDepth	1
modified	[InstanceEdit:9964317] Matthews, Lisa, 2025-08-22
name	Spike binds Spike inhibitors
negativePrecedingEvent	[NegativePrecedingEvent:9763981] Futile Cycle: Viral release
output	[Complex:R-COV-9707788] Spike:Spike inhibitors [extracellular region]
relatedSpecies	[Species:9681683] Severe acute respiratory syndrome coronavirus 2
releaseDate	2022-06-09
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
revised	[InstanceEdit:9733146] Stephan, Ralf, 2021-06-01
schemaClass	Reaction
species	[Species:48887] Homo sapiens
stId	R-HSA-9707827
summation	[Summation:9707813] SARS?CoV?2 infection begins with the binding of viral S (spi...

Referrals

(hasEvent)

[Pathway:R-HSA-9694614] Attachment and Entry

Cite Us!